Growing community of inventors

Cuenca, Spain

MaLuisa Ballesteros Jarreno

Average Co-Inventor Count = 14.01

ph-index = 1

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 6

MaLuisa Ballesteros JarrenoLuis Enjuanes Sanchez (1 patent)MaLuisa Ballesteros JarrenoJuan Plana Duran (1 patent)MaLuisa Ballesteros JarrenoZoltán Penzes (1 patent)MaLuisa Ballesteros JarrenoJosé Manuel Gonzalez Martinez (1 patent)MaLuisa Ballesteros JarrenoCarlos Miguel Sanchez Sanchez (1 patent)MaLuisa Ballesteros JarrenoMaria Muntion Saenz (1 patent)MaLuisa Ballesteros JarrenoJoaquin Castilla Castrillon (1 patent)MaLuisa Ballesteros JarrenoJosé Manuel Sanchez Morgado (1 patent)MaLuisa Ballesteros JarrenoAnder Izeta Parmesan (1 patent)MaLuisa Ballesteros JarrenoCristina Smerdou Picazo (1 patent)MaLuisa Ballesteros JarrenoIsabel Sola Gurpegui (1 patent)MaLuisa Ballesteros JarrenoSara Alonso Villanueva (1 patent)MaLuisa Ballesteros JarrenoAna Mendez Zunzunegui (1 patent)MaLuisa Ballesteros JarrenoMaLuisa Ballesteros Jarreno (1 patent)Luis Enjuanes SanchezLuis Enjuanes Sanchez (3 patents)Juan Plana DuranJuan Plana Duran (2 patents)Zoltán PenzesZoltán Penzes (1 patent)José Manuel Gonzalez MartinezJosé Manuel Gonzalez Martinez (1 patent)Carlos Miguel Sanchez SanchezCarlos Miguel Sanchez Sanchez (1 patent)Maria Muntion SaenzMaria Muntion Saenz (1 patent)Joaquin Castilla CastrillonJoaquin Castilla Castrillon (1 patent)José Manuel Sanchez MorgadoJosé Manuel Sanchez Morgado (1 patent)Ander Izeta ParmesanAnder Izeta Parmesan (1 patent)Cristina Smerdou PicazoCristina Smerdou Picazo (1 patent)Isabel Sola GurpeguiIsabel Sola Gurpegui (1 patent)Sara Alonso VillanuevaSara Alonso Villanueva (1 patent)Ana Mendez ZunzuneguiAna Mendez Zunzunegui (1 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Cyanamid Iberica, S.a. (1 from 2 patents)


1 patent:

1. 7041300 - Vectors based on recombinant defective viral genomes, and their use in the formulation of vaccines

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/19/2025
Loading…